Gilgamesh Pharma Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
30
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$62.2M
- Investors
-
27
Gilgamesh Pharma General Information
Description
Developer of novel chemical entities designed to transform the treatment of psychiatric disorders through rapid-acting and durable therapies. The company offers AI-powered drug discovery capabilities, advanced medicinal chemistry expertise, and orally bioavailable neuroactive compounds with improved safety profiles, enabling patients with depression, anxiety, and substance use disorders to achieve faster relief and sustained therapeutic effects.
Contact Information
Website
www.gilgameshpharmaceutical.comCorporate Office
- 113 University Place
- Suite 1019
- New York, NY 10003
- United States
Corporate Office
- 113 University Place
- Suite 1019
- New York, NY 10003
- United States
Gilgamesh Pharma Timeline
Gilgamesh Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series A) | 31-Mar-2026 | $62.2M | Completed | Clinical Trials - Phase 2 | ||
| 4. Grant | 14-Mar-2024 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series B) | 19-May-2022 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 26-Apr-2021 | $27M | $34.6M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC (Series A) | 22-Jul-2020 | $7.6M | $7.6M | Completed | Clinical Trials - Phase 1 |
Gilgamesh Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A-6 | ||||||||
| Series A-5 | ||||||||
| Series A-4 | ||||||||
| Series A-3 | ||||||||
| Series A-2 | ||||||||
| Series A-1 | 70,699 | $0.000100 | $3.54 | $3.54 | 1x | $3.54 | 0.35% | |
| Series A | 4,465,217 | $0.000100 | $6.05 | $6.05 | 1x | $6.05 | 21.88% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Gilgamesh Pharma Comparisons
Industry
Financing
Details
Gilgamesh Pharma Competitors (8)
One of Gilgamesh Pharma’s 8 competitors is COMPASS Pathways, a Formerly VC-backed company based in Altrincham, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| COMPASS Pathways | Formerly VC-backed | Altrincham, United Kingdom | ||||
| Delix Therapeutics | Venture Capital-Backed | Concord, MA | ||||
| Bright Minds | Formerly VC-backed | New York, NY | ||||
| Longboard Pharmaceuticals | Formerly VC-backed | La Jolla, CA | ||||
| AtaiBeckley | Formerly VC-backed | New York, NY |
Gilgamesh Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Gilgamesh Pharma Patents
Gilgamesh Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026193329-A1 | Crystalline salts of 1-(2,5-dimethoxy-4-propylphenyl)-3-methoxypropan-2-amine | Pending | 12-Mar-2025 | ||
| WO-2026193320-A1 | Crystalline salts of 1-(4-allyl-2,5-dimethoxyphenyl)butan-2-amine | Pending | 12-Mar-2025 | ||
| WO-2026193220-A1 | Novel phenylalkylamines and their use in the treatment of psychiatric disorders | Pending | 12-Mar-2025 | ||
| WO-2026178240-A1 | A treatment for patients with mood disorders using n-ethyl-2-(5- fluoro-17/-indol-3-yl)-a-methylethan-l-amine or a pharmaceutically acceptable salt thereof | Pending | 20-Feb-2025 | ||
| AU-2025376445-A1 | Methods of treating psychiatric disorders or pain using (r)-2-(4-fluorophenyl)-2-(methylamino)cyclohexan-1-one or pharmaceutically acceptable salts thereof | Pending | 13-May-2024 |
Gilgamesh Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Gilgamesh Pharma Investors (27)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BroadVision Group | Venture Capital | Minority | ||
| Dragonfly 44 Capital | Venture Capital | Minority | ||
| Magnetic Ventures | Venture Capital | Minority | ||
| Shoe Investments | Venture Capital | Minority | ||
| Threshold Potential | Venture Capital | Minority |
Gilgamesh Pharma FAQs
-
When was Gilgamesh Pharma founded?
Gilgamesh Pharma was founded in 2019.
-
Where is Gilgamesh Pharma headquartered?
Gilgamesh Pharma is headquartered in New York, NY.
-
What is the size of Gilgamesh Pharma?
Gilgamesh Pharma has 30 total employees.
-
What industry is Gilgamesh Pharma in?
Gilgamesh Pharma’s primary industry is Drug Discovery.
-
Is Gilgamesh Pharma a private or public company?
Gilgamesh Pharma is a Private company.
-
What is the current valuation of Gilgamesh Pharma?
The current valuation of Gilgamesh Pharma is .
-
What is Gilgamesh Pharma’s current revenue?
The current revenue for Gilgamesh Pharma is .
-
How much funding has Gilgamesh Pharma raised over time?
Gilgamesh Pharma has raised $136M.
-
Who are Gilgamesh Pharma’s investors?
BroadVision Group, Dragonfly 44 Capital, Magnetic Ventures, Shoe Investments, and Threshold Potential are 5 of 27 investors who have invested in Gilgamesh Pharma.
-
Who are Gilgamesh Pharma’s competitors?
COMPASS Pathways, Delix Therapeutics, Bright Minds, Longboard Pharmaceuticals, and AtaiBeckley are some of the 8 competitors of Gilgamesh Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
